Lifeward Ltd. filed a Form 8-K on October 27, 2026, disclosing the appointment of Ronen Tsimerman, age 56, as Chief Financial Officer, principal financial officer, and principal accounting officer, effective November 1, 2026.

Key Highlights

  • New CFO appointed: Ronen Tsimerman, age 56, was appointed by the Board of Directors on October 26, 2026, with an effective date of November 1, 2026.
  • Prior role: Tsimerman most recently served as chief financial officer of Scopio Labs Ltd. from August through October 2026.
  • Longer prior tenure: He served as CFO of IceCure Medical Ltd (Nasdaq: ICCM) from May 2017 to August 2026, and as its chief operating officer from May 2018 to November 2025.
  • Base salary: The employment agreement provides for a gross monthly base salary of NIS 70,000, subject to shareholder approval of the Renewed Compensation Policy at the annual general meeting scheduled for October 30, 2026.
  • Bonus structure: An annual performance-based bonus, with a target of not less than four monthly salaries, plus a transaction bonus, are included in the compensation terms.
  • Notice period: The agreement provides a 3-month notice period for termination, increasing to four months following any change in the Company's Chief Executive Officer.
  • No related-party ties: According to the filing, Tsimerman has no family relationship with any director or executive officer of the Company.

Lifeward Board Appoints Experienced Finance Executive as CFO

According to the Form 8-K filed with the SEC on October 27, 2026, Lifeward Ltd. (NASDAQ:LFWD) disclosed that its Board of Directors appointed Ronen Tsimerman as CFO, principal financial officer, and principal accounting officer on October 26, 2026, with the appointment taking effect November 1, 2026. The filing identifies Tsimerman as "an experienced global finance executive" and traces his background across multiple publicly listed companies.

The filing states that Tsimerman most recently held the CFO role at Scopio Labs Ltd. from August through October 2026. Before that, he served as CFO of IceCure Medical Ltd (Nasdaq: ICCM) from May 2017 to August 2026 and as its COO from May 2018 to November 2025. Earlier positions include CFO of Insuline Medical Ltd. (TASE: INSL) from May 2015 to May 2017, CFO of Mer-Group Broadband division (TASE: CMER) from 2005 to 2013, and vice president of finance of Mer-Group Telecom Division from 2013 to 2014. The filing notes he holds a bachelor's degree in business and an MBA from the College of Management in Israel.

The Company and Tsimerman will enter into an employment agreement subject to shareholder approval of the Renewed Compensation Policy at the Company's annual general meeting to be held on October 30, 2026. The CFO Employment Agreement, as described in the filing, provides for a gross monthly base salary of NIS 70,000, an annual performance-based bonus with a target of not less than four monthly salaries, and a transaction bonus. The filing also states that the Company entered into its "standard indemnification, insurance and exculpation agreement" with Tsimerman in connection with his appointment. The 8-K was signed by Josh Hexter, identified as Interim Chief Executive Officer.

What Was Disclosed

Lifeward Ltd. disclosed the Board-approved appointment of Ronen Tsimerman as CFO effective November 1, 2026, including his professional background, the key terms of his pending employment agreement, and confirmation of no related-party conflicts or undisclosed arrangements.